International multicenter randomized phase III study of first-line erlotinib (E) followed by second-line cisplatin plus gemcitabine (CG) versus first-line CG followed by second-line E in advanced non-small cell lung cancer (aNSCLC): The TORCH trial

被引：37

作者：

Gridelli, C.

Ciardiello, F.

Feld, R.

Butts, C. A.

Gebbia, V.

Genestreti, G.

Favaretto, A. G.

Wierzbicki, R.

Gallo, C.

Perrone, F.

机构：

[1] San Giuseppe Moscati Hosp, Avellino, Italy

[2] Univ Naples 2, Naples, Italy

[3] Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada

[4] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada

[5] La Maddalena Clin, Palermo, Italy

[6] AO Morgagni Pierantoni, Forli, Italy

[7] Ist Oncol Veneto, Padua, Italy

[8] Durham Reg Canc Ctr, Oshawa, ON, Canada

[9] Natl Canc Inst, Clin Trials Unit, Naples, Italy

来源：

关键词：

D O I：

10.1200/jco.2010.28.15_suppl.7508

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7508

引用

页数：1